Expired activity
Please go to the PowerPak homepage and select a course.

PHARMACY PrEP EDUCATION A “How To” Series Spanning Policy to Practice

Providing PEP/PrEP in the Pharmacy Setting: A Comprehensive User Guide

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Gilead Sciences, Inc.

Release Date: July 29, 2022

Expiration Date: July 29, 2023


This comprehensive electronic/downloadable monograph has been developed to specifically support the needs of pharmacists now challenged to come up to speed on guidelines and protocols for HIV preexposure and postexposure prophylaxis (PrEP and PEP). A number of states in the United States have expanded the pharmacy scope of practice and this continuing education activity will provide the necessary clinical information for initiating and monitoring PrEP and PEP treatment in a pharmacy setting. In December 2021, the Centers for Disease Control and Prevention (CDC) released the 2021 Updated PrEP Clinical Practice Guidelines, and pharmacists now need to be trained to incorporate these updated guidelines into their daily practice. Providing 2.0 contact hour(s) (0.20 CEUs) from the Accreditation Council for Pharmacy Education, this monograph addresses all content to fulfill most state Board of Pharmacy training requirements for pharmacists wishing to become PrEP and PEP providers, such as:

  • HIV epidemiology

  • Pharmacology, safety, and efficacy of HIV medications used for PEP and PrEP (including oral tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), oral tenofovir alafenamide (TAF)/FTC, and long-acting injectable cabotegravir)

  • Assessment of sexual health and HIV risk

  • Trauma-informed care

  • Patient counseling

  • Screening for HIV and sexually transmitted infections (STIs), and laboratory testing to determine PrEP/PEP eligibility

  • 2021 CDC Updated PrEP Clinical Practice Guidelines for PrEP eligibility, prescribing, and management

  • Clinical practice guidelines for PEP eligibility, prescribing, and management

  • In-pharmacy implementation

Target Audience

The educational design of this monograph addresses the needs of clinical and community pharmacists involved in the treatment of patients at risk for HIV infection as well as managed care pharmacists, pharmacy benefit managers, and specialty pharmacists.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the legal and professional parameters that allow for pharmacist-led or pharmacy-based direct delivery of postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) services

  • Assess patient’s risk of HIV acquisition based on the type of exposure

  • Determine patients’ PEP/PrEP eligibility through HIV testing, sexual history-taking, and appropriate laboratory testing

  • Implement guideline-driven PEP/PrEP-prescribing principles regarding treatment initiation, monitoring, and referral

  • Identify infrastructure needs for in-pharmacy implementation of a PEP/PrEP prescribing initiative


Melissa Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP

Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois

Shauna Applin, A-NP, AAHIVs

HIV Clinical Director
Adult Medicine Lead Provider
Community Health Care
Hilltop Regional Medical Center
Tacoma, Washington

Pharmacist Accreditation Statement

Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-22-063-H02-P)

This is a knowledge-based activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.

  2. Complete the Preactivity Questions.

  3. Review the activity content.

  4. Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.

  5. CE credits will be uplaoded to CPE Monitor within 60 days of completion.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Melissa Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP Nothing to disclose
Shauna Applin, A-NP, AAHIVs Consulting Fee: Gilead, Janssen, Merck
Contracted Research: Gilead (PI)
Speakers’ Bureau: Gilead, Merck

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Stacey Ullman, MHS Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.